Digital versus Local Anesthesia for Finger Lacerations: A Randomized Controlled Trial

2006 ◽  
Vol 13 (10) ◽  
pp. 1046-1050 ◽  
Author(s):  
Stuart Chale ◽  
Adam J. Singer ◽  
Scott Marchini ◽  
Mary Jo McBride ◽  
David Kennedy
Keyword(s):  
Randomized Controlled Trial ◽  
Local Anesthesia ◽  
Controlled Trial ◽  
Randomized Controlled

TWIN MIXED LOCAL ANESTHESIA IN THIRD MOLAR SURGERY - RANDOMIZED CONTROLLED TRIAL

2021 ◽  
Author(s):  
Shivangi Gaur ◽  
Madhulaxmi Marimuthu ◽  
P Wahab ◽  
Dr Navaneetha Krishnan ◽  
Subhashini Ramasubbu
Keyword(s):  
Randomized Controlled Trial ◽  
Local Anesthesia ◽  
Controlled Trial ◽  
Third Molar ◽  
Third Molar Surgery ◽  
Randomized Controlled

scholarly journals Local Anesthesia Versus Local Anesthesia and Conscious Sedation for Inguinal Hernioplasty: Protocol of a Randomized Controlled Trial

2017 ◽  
Vol 6 (2) ◽  
pp. e20 ◽  
Author(s):  
Pierre-Anthony Leake ◽  
Patrick J Toppin ◽  
Marvin Reid ◽  
Joseph M Plummer ◽  
Patrick O Roberts ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Local Anesthesia ◽  
Conscious Sedation ◽  
Controlled Trial ◽  
Inguinal Hernioplasty ◽  
Randomized Controlled

scholarly journals Long-Term Functional Patency and Cost-Effectiveness of Arteriovenous Fistula Creation under Regional Anesthesia: a Randomized Controlled Trial

2020 ◽  
Vol 31 (8) ◽  
pp. 1871-1882
Author(s):  
Emma Aitken ◽  
Rachel Kearns ◽  
Lucian Gaianu ◽  
Andrew Jackson ◽  
Mark Steven ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Cost Effectiveness ◽  
Local Anesthesia ◽  
Regional Anesthesia ◽  
Controlled Trial ◽  
Secondary Patency ◽  
University Hospitals ◽  
Clinical Trial Registry ◽  
Randomized Controlled ◽  
Life Years

BackgroundRegional anesthesia improves short-term blood flow through arteriovenous fistulas (AVFs). We previously demonstrated that, compared with local anesthesia, regional anesthesia improves primary AVF patency at 3 months.MethodsTo study the effects of regional versus local anesthesia on longer-term AVF patency, we performed an observer-blinded randomized controlled trial at three university hospitals in Glasgow, United Kingdom. We randomly assigned 126 patients undergoing primary radiocephalic or brachiocephalic AVF creation to receive regional anesthesia (brachial plexus block; 0.5% L-bupivacaine and 1.5% lidocaine with epinephrine) or local anesthesia (0.5% L-bupivacaine and 1% lidocaine). This report includes findings on primary, functional, and secondary patency at 12 months; reinterventions; and additional access procedures (primary outcome measures were previously reported). We analyzed data by intention to treat, and also performed cost-effectiveness analyses.ResultsAt 12 months, we found higher primary patency among patients receiving regional versus local anesthesia (50 of 63 [79%] versus 37 of 63 [59%] patients; odds ratio [OR], 2.7; 95% confidence interval [95% CI], 1.6 to 3.8; P=0.02) as well as higher functional patency (43 of 63 [68%] versus 31 of 63 [49%] patients; OR, 2.1; 95% CI, 1.5 to 2.7; P=0.008). In 12 months, 21 revisional procedures, 53 new AVFs, and 50 temporary dialysis catheters were required. Regional anesthesia resulted in net savings of £195.10 (US$237.36) per patient at 1 year, and an incremental cost-effectiveness ratio of approximately £12,900 (US$15,694.20) per quality-adjusted life years over a 5-year time horizon. Results were robust after extensive sensitivity and scenario analyses.ConclusionsCompared with local anesthesia, regional anesthesia significantly improved both primary and functional AVF patency at 1 year and is cost-effective.Clinical Trial registry name and registration numberLocal Anaesthesia versus Regional Block for Arteriovenous Fistulae, NCT01706354

A Phase 1, Dose-escalation, Double-blind, Block-randomized, Controlled Trial of Safety and Efficacy of Neosaxitoxin Alone and in Combination with 0.2% Bupivacaine, with and without Epinephrine, for Cutaneous Anesthesia

2015 ◽  
Vol 123 (4) ◽  
pp. 873-885 ◽  
Author(s):  
Kimberly Lobo ◽  
Carolina Donado ◽  
Laura Cornelissen ◽  
Joseph Kim ◽  
Rebeca Ortiz ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Adverse Events ◽  
Local Anesthesia ◽  
Active Sites ◽  
Peak Plasma ◽  
Controlled Trial ◽  
Phase 1 ◽  
Double Blind ◽  
Safety And Efficacy ◽  
Randomized Controlled

Abstract Background: Neosaxitoxin (NeoSTX) is a site-1 sodium channel blocker that produces prolonged local anesthesia in animals and humans. Under a Food and Drug Administration–approved phase 1 Investigational New Drug trial, the authors evaluated safety and efficacy of NeoSTX alone and combined with 0.2% bupivacaine (Bup) with and without epinephrine. Methods: The authors conducted a double-blind, randomized, controlled trial involving healthy male volunteers aged 18 to 35 yr receiving two 10-ml subcutaneous injections. Control sites received Bup. In part 1, active sites received (1) 5 to 40 μg NeoSTX+Saline (NeoSTX-Saline), (2) 5 to 40 μg NeoSTX+Bup (NeoSTX-Bup), or (3) placebo (Saline). In part 2, active sites received 10 or 30 μg NeoSTX+Bup+Epinephrine (NeoSTX-Bup-Epi) or placebo. Primary outcome measures were safety and adverse events associated with NeoSTX. Secondary outcomes included clinical biochemistry, NeoSTX pharmacokinetics, and cutaneous hypoesthesia. Results: A total of 84 subjects were randomized and completed the two-part trial with no serious adverse events or clinically significant physiologic impairments. Perioral numbness and tingling increased with NeoSTX dose for NeoSTX-Saline and NeoSTX-Bup. All symptoms resolved without intervention. NeoSTX-Bup-Epi dramatically reduced symptoms compared with other NeoSTX combinations (tingling: 0 vs. 70%, P = 0.004; numbness: 0 vs. 60%, P = 0.013) at the same dose. Mean peak plasma NeoSTX concentration for NeoSTX-Bup-Epi was reduced at least two-fold compared with NeoSTX-Saline and NeoSTX-Bup (67 ± 14, 134 ± 63, and 164 ± 81 pg/ml, respectively; P = 0.016). NeoSTX-Bup showed prolonged cutaneous block duration compared with Bup, NeoSTX-Saline, or placebo, at all doses. Median time to near-complete recovery for 10 μg NeoSTX-Bup-Epi was almost five-fold longer compared with Bup (50 vs. 10 h, P = 0.007). Conclusion: NeoSTX combinations have a tolerable side effect profile and appear promising for prolonged local anesthesia.

scholarly journals The Combination of Ketorolac with Local Anesthesia for Pain Control in Day Care Retinal Detachment Surgery: A Randomized Controlled Trial

2017 ◽  
Vol 2017 ◽  
pp. 1-8
Author(s):  
Xiaohong Chen ◽  
Bingqian Liu ◽  
Xiaoling Liang ◽  
Jiaqing Li ◽  
Tao Li ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Retinal Detachment ◽  
Local Anesthesia ◽  
Day Care ◽  
Pain Control ◽  
Controlled Trial ◽  
Postoperative Nausea And Vomiting ◽  
Analgesic Requirement ◽  
Retinal Detachment Surgery ◽  
Randomized Controlled

This study aims to evaluate the efficacy of ketorolac with local anesthesia compared to local anesthesia alone for perioperative pain control in day care retinal detachment surgery. The randomized controlled trial included 59 eyes of 59 participants for retinal detachment surgery who were randomly assigned (1 : 1) into the ketorolac (K) group and control (C) group. All participants underwent conventional local anesthesia while patients in the K group received an extra administration of preoperative ketorolac. Participants in the K group had a statistically significantly lower intraoperative NRS score (median 1.0 versus 3.0, P=0.003), lower postoperative NRS score (median 0 versus 1.0, P=0.035), fewer proportion of rescue analgesic requirement (10% versus 34.5%, P=0.023), and lower incidence of postoperative nausea and vomiting (13.3% versus 41.4%, P=0.015) compared to the C group. Intraocular pressure (IOP) changes (△IOP) were significantly reduced in the K group (median 1.9 versus 3.0, P=0.038) compared to the C group 24 hours postoperatively. In conclusion, the combination of local anesthesia with ketorolac provides better pain control in retinal detachment surgery compared to local anesthesia alone. The beneficial effect of ketorolac with local anesthesia may contribute to a wider-spread adoption of day care retinal detachment surgery. This trial is registered with ClinicalTrials.gov NCT02729285.

Sign in / Sign up

Export Citation Format

Share Document